Q-omics provides the consensus-scored KAT6B profile across patient tissues and cancer cell-line models. KAT6B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KAT6B is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, KAT6B RNA expression shows 22,496 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where KAT6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KAT6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KAT6B survival associations across molecular data types. KAT6B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KAT6B RNA expression–survival associations across cancer types. High KAT6B expression shows unfavorable associations in UVM, but favorable associations in KIRC, SCLC, LGG, UCS and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KAT6B RNA expression.
This table summarizes KAT6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in BLCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for KAT6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KAT6B shows lower tumor expression in BLCA, COAD and LUAD and higher tumor expression in BRCA, LIHC and CHOL. The BLCA box plot shows higher KAT6B RNA expression in normal versus tumor tissue (log2 FC = −0.945, t-test p < 0.001).
This table shows molecular features associated with KAT6B in patient tissues and cancer cell lines. In patient samples, KAT6B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KAT6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
